LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Suchergebnis

Treffer 1 - 10 von insgesamt 57

Suchoptionen

  1. Artikel: Characterizing Ertapenem Neurotoxicity: A Systematic Review and Experience at a Tertiary Medical Center.

    Mitaka, Hayato / Hasegawa, Shinya / Lan, Kristine F / Jain, Rupali / Rakita, Robert M / Pottinger, Paul S

    Open forum infectious diseases

    2024  Band 11, Heft 5, Seite(n) ofae214

    Abstract: Ertapenem-induced neurotoxicity has not been well characterized and is potentially underreported. We conducted a systematic review of the literature and included 11 additional cases from the University of Washington Medicine health system. A total of 125 ...

    Abstract Ertapenem-induced neurotoxicity has not been well characterized and is potentially underreported. We conducted a systematic review of the literature and included 11 additional cases from the University of Washington Medicine health system. A total of 125 individual patient cases were included in the data analysis. The mean age was 72 years, and 62% and 42% of patients had renal dysfunction and preexisting central nervous system (CNS) conditions, respectively. Only 15% of patients received inappropriately high ertapenem dosing based on kidney function. Patients developed neurological signs and symptoms after a median of 4 days (interquartile range, 3-9 days). The most common clinical features were seizures (70%), altered level of consciousness or delirium (27%), and hallucinations (17%). An estimated incidence in our health system was 1 in 102 courses of ertapenem. Ertapenem neurotoxicity should be suspected when a patient with renal dysfunction or predisposing CNS conditions develops neurological signs and symptoms, especially within several days after initiating the antibiotic. This study underscores the need for a large prospective study to assess the true incidence and outcomes of ertapenem neurotoxicity.
    Sprache Englisch
    Erscheinungsdatum 2024-04-16
    Erscheinungsland United States
    Dokumenttyp Clinical Trial
    ZDB-ID 2757767-3
    ISSN 2328-8957
    ISSN 2328-8957
    DOI 10.1093/ofid/ofae214
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  2. Artikel ; Online: Response to Yates and Halliday regarding CMV DNAemia and time-to-mortality in a Randomized Trial of PET vs AP in CMV D+R-Liver Transplant Recipients.

    Kumar, Lakshin / Dasgupta, Sayan / Murray-Krezan, Cristina / Singh, Nina / Rakita, Robert M / Fisher, Cynthia E / Limaye, Ajit P

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

    2024  

    Sprache Englisch
    Erscheinungsdatum 2024-01-08
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 1099781-7
    ISSN 1537-6591 ; 1058-4838
    ISSN (online) 1537-6591
    ISSN 1058-4838
    DOI 10.1093/cid/ciae005
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  3. Artikel ; Online: A practical guide to real-world implementation of pre-emptive therapy for Cytomegalovirus disease prevention in high-risk seronegative liver transplant recipients with seropositive donors.

    Heldman, Madeleine R / Dunn, Bailey / Clemens, Evan / Henderson, Megan / Fisher, Cynthia E / Rakita, Robert M / Kling, Catherine E / Limaye, Ajit P

    Transplant infectious disease : an official journal of the Transplantation Society

    2024  , Seite(n) e14229

    Abstract: The Comparison of Antiviral Preventative Strategies In Liver Transplant (CAPSIL) study showed pre-emptive therapy (PET) to be superior to antiviral prophylaxis for Cytomegalovirus (CMV) disease prevention in high-risk CMV seronegative liver transplant ... ...

    Abstract The Comparison of Antiviral Preventative Strategies In Liver Transplant (CAPSIL) study showed pre-emptive therapy (PET) to be superior to antiviral prophylaxis for Cytomegalovirus (CMV) disease prevention in high-risk CMV seronegative liver transplant recipients (LTRs) with seropositive donors (D
    Sprache Englisch
    Erscheinungsdatum 2024-01-12
    Erscheinungsland Denmark
    Dokumenttyp Journal Article
    ZDB-ID 1476094-0
    ISSN 1399-3062 ; 1398-2273
    ISSN (online) 1399-3062
    ISSN 1398-2273
    DOI 10.1111/tid.14229
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  4. Artikel ; Online: Apples to apples: The challenges of studying COVID-19 mortality in solid organ transplant recipients.

    Heldman, Madeleine R / Rakita, Robert M / Lease, Erika D / Fisher, Cynthia E / Limaye, Ajit P

    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

    2022  Band 22, Heft 7, Seite(n) 1929–1930

    Mesh-Begriff(e) COVID-19 ; Humans ; Malus ; Organ Transplantation ; SARS-CoV-2 ; Transplant Recipients
    Sprache Englisch
    Erscheinungsdatum 2022-02-15
    Erscheinungsland United States
    Dokumenttyp Letter ; Research Support, N.I.H., Extramural ; Comment
    ZDB-ID 2060594-8
    ISSN 1600-6143 ; 1600-6135
    ISSN (online) 1600-6143
    ISSN 1600-6135
    DOI 10.1111/ajt.16989
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  5. Artikel: A Systematic Review and Meta-analysis of Optimized CMV Preemptive Therapy and Antiviral Prophylaxis for CMV Disease Prevention in CMV High-Risk (D+R-) Kidney Transplant Recipients.

    Kumar, Lakshin / Murray-Krezan, Cristina / Singh, Nina / Brennan, Daniel C / Rakita, Robert M / Dasgupta, Sayan / Fisher, Cynthia E / Limaye, Ajit P

    Transplantation direct

    2023  Band 9, Heft 8, Seite(n) e1514

    Abstract: The optimal strategy for cytomegalovirus (CMV) disease prevention in CMV donor/recipient kidney transplant recipients remains uncertain. Conclusions of prior meta-analyses that CMV disease rates with preemptive therapy (PET) and universal prophylaxis (UP) ...

    Abstract The optimal strategy for cytomegalovirus (CMV) disease prevention in CMV donor/recipient kidney transplant recipients remains uncertain. Conclusions of prior meta-analyses that CMV disease rates with preemptive therapy (PET) and universal prophylaxis (UP) were comparable may have been affected by inclusion of studies lacking key determinants of efficacy of the respective strategies.
    Methods: We conducted a systematic review and meta-analysis of PET with weekly CMV polymerase chain reaction monitoring for ≥3 mo and UP with 6 mo of valganciclovir. PubMed and Embase databases were reviewed from January 1, 2010, to April 1, 2022. Risk of bias was assessed with 3 instruments (Cochrane RoB, Cochrane RoBINS-I, and an instrument for assessing risk in observational studies). The primary outcome was CMV disease incidence by 1-y posttransplant. Secondary outcomes by 1-y were graft loss, acute allograft rejection, and mortality. Results were synthesized using generalized linear mixed model meta-analysis. PET studies were stratified into low-threshold (LT) and high-threshold (HT) PET based on the viral load threshold for initiation of antiviral therapy.
    Results: Twenty-five studies met inclusion criteria (6 PET, 19 UP). CMV disease incidence was significantly higher in HT (0.30 [95% confidence interval (CI), 0.22-0.39]) versus LT PET (0.06 [95% CI, 0.03-0.12]). LT PET was associated with a significantly lower CMV disease incidence (0.06 [95% CI, 0.03-0.12]) versus UP (0.21 [95% CI, 0.17-0.27]). Incidence of graft loss, acute allograft rejection, or mortality was not significantly different between LT PET and UP (
    Conclusions: LT PET is associated with a significantly lower incidence of CMV disease compared to UP with similar rates of other clinical outcomes. These findings provide rationale and preliminary data for a randomized superiority trial of optimized LT-PET versus UP in donor seropositive recipient seronegative kidney transplant recipients.
    Sprache Englisch
    Erscheinungsdatum 2023-07-12
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ISSN 2373-8731
    ISSN 2373-8731
    DOI 10.1097/TXD.0000000000001514
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  6. Artikel ; Online: Association of Cytomegalovirus (CMV) DNAemia With Long-Term Mortality in a Randomized Trial of Preemptive Therapy and Antiviral Prophylaxis for Prevention of CMV Disease in High-Risk Donor Seropositive, Recipient Seronegative Liver Transplant Recipients.

    Kumar, Lakshin / Dasgupta, Sayan / Murray-Krezan, Cristina / Singh, Nina / Rakita, Robert M / Fisher, Cynthia E / Limaye, Ajit P

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

    2023  Band 78, Heft 3, Seite(n) 719–722

    Abstract: In a post-hoc analysis of the association of CMV DNAemia with long-term mortality in a randomized trial of CMV preemptive therapy vs. antiviral prophylaxis in D+R- liver transplant recipients, post-intervention CMV DNAemia was associated with increased ... ...

    Abstract In a post-hoc analysis of the association of CMV DNAemia with long-term mortality in a randomized trial of CMV preemptive therapy vs. antiviral prophylaxis in D+R- liver transplant recipients, post-intervention CMV DNAemia was associated with increased mortality after adjusting for study arm.
    Mesh-Begriff(e) Humans ; Antiviral Agents/therapeutic use ; Cytomegalovirus/genetics ; Cytomegalovirus Infections/drug therapy ; Liver Transplantation ; Tissue Donors ; Transplant Recipients ; Randomized Controlled Trials as Topic
    Chemische Substanzen Antiviral Agents
    Sprache Englisch
    Erscheinungsdatum 2023-10-19
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 1099781-7
    ISSN 1537-6591 ; 1058-4838
    ISSN (online) 1537-6591
    ISSN 1058-4838
    DOI 10.1093/cid/ciad643
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  7. Artikel ; Online: Real-world effectiveness of preemptive therapy (PET) for cytomegalovirus (CMV) disease prevention in CMV high-risk donor seropositive/recipient seronegative (D+R-) liver transplant recipients (LTxR).

    Doss, Kathleen M / Kling, Catherine E / Heldman, Madeleine R / Singh, Nina / Wagener, Marilyn / Rakita, Robert M / Fisher, Cynthia E / Limaye, Ajit P

    Transplant infectious disease : an official journal of the Transplantation Society

    2023  Band 25, Heft 2, Seite(n) e14015

    Abstract: Background: Despite superiority of preemptive therapy (PET) compared to universal prophylaxis for prevention of cytomegalovirus (CMV) disease in the CAPSIL randomized trial among CMV D+R- liver transplant recipients (LTxRs), real-world effectiveness may ...

    Abstract Background: Despite superiority of preemptive therapy (PET) compared to universal prophylaxis for prevention of cytomegalovirus (CMV) disease in the CAPSIL randomized trial among CMV D+R- liver transplant recipients (LTxRs), real-world effectiveness may be lower because of logistical concerns about feasibility of PET.
    Methods: We retrospectively assessed PET as standard clinical care at a single transplant center among 50 consecutive adult CMV D+R- LTxRs undergoing a first liver transplant between 4/4/2019 and 5/18/2021 and compared outcomes and adherence to those randomized to PET in the CAPSIL study (N = 100). The primary outcome was CMV disease and secondary outcomes were biopsy-confirmed acute allograft rejection, retransplant, invasive fungal infections, and death, all assessed by 1-year post-transplant. Exploratory outcomes included virologic parameters and measures of adherence to protocol-specified CMV qPCR monitoring.
    Results: Baseline characteristics were similar between groups. The cumulative incidence of CMV disease at 1-year post-transplant was 4/50 (8%) versus 9/100 (9%) in the real-world and CAPSIL cohorts, respectively, p = 1.0. The rate of breakthrough CMV disease during the 100-day PET period was low (2/50 [4%]) and similar to the PET cohort from the CAPSIL study (3/100 [3%]).  All secondary and exploratory outcomes were not significantly different between the real-world and CAPSIL PET cohorts.
    Conclusions: In this first reported study of real-world PET, the feasibility and effectiveness for CMV disease prevention and for other clinical outcomes in CMV D+R- LTxRs were similar to those reported with PET in a clinical trial. Additional studies to confirm feasibility and generalizability in other settings are warranted.
    Mesh-Begriff(e) Adult ; Humans ; Cytomegalovirus ; Antiviral Agents/therapeutic use ; Liver Transplantation/adverse effects ; Retrospective Studies ; Treatment Outcome ; Cytomegalovirus Infections/epidemiology ; Cytomegalovirus Infections/prevention & control ; Cytomegalovirus Infections/drug therapy ; Positron-Emission Tomography/adverse effects ; Transplant Recipients ; Ganciclovir/therapeutic use
    Chemische Substanzen Antiviral Agents ; Ganciclovir (P9G3CKZ4P5)
    Sprache Englisch
    Erscheinungsdatum 2023-02-03
    Erscheinungsland Denmark
    Dokumenttyp Randomized Controlled Trial ; Journal Article
    ZDB-ID 1476094-0
    ISSN 1399-3062 ; 1398-2273
    ISSN (online) 1399-3062
    ISSN 1398-2273
    DOI 10.1111/tid.14015
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  8. Artikel ; Online: Combined assessment of Epstein-Barr virus viral capsid antigen and Epstein-Barr virus nuclear antigen-1 serology for post-transplant lymphoproliferative disorder risk stratification in adult solid organ transplant recipients.

    Heldman, Madeleine R / Edlefsen, Kerstin L / Pepper, Gregory / Kapnadak, Siddhartha G / Rakita, Robert M / Fisher, Cynthia E / Limaye, Ajit P

    Transplant infectious disease : an official journal of the Transplantation Society

    2022  Band 24, Heft 6, Seite(n) e13933

    Abstract: Background: Epstein-Barr virus (EBV) seronegative solid organ transplant recipients (SOTRs) are at increased risk for post-transplant lymphoproliferative disorder (PTLD). Assays for EBV serostatus assess antibody to both EBV viral capsid antigen (VCA) ... ...

    Abstract Background: Epstein-Barr virus (EBV) seronegative solid organ transplant recipients (SOTRs) are at increased risk for post-transplant lymphoproliferative disorder (PTLD). Assays for EBV serostatus assess antibody to both EBV viral capsid antigen (VCA) and Epstein-Barr nuclear antigen-1 (EBNA-1), but PTLD risk among SOT recipients with discordant VCA and EBNA-1 results is unknown.
    Methods: We performed a retrospective, single-center cohort study to determine the risk of PTLD among adult (≥ 18 years) SOTRs with discordant pre-transplant VCA and EBNA-1 IgG compared to that of SOTRs with concordantly negative or concordantly positive serology using univariable and multivariable Cox-proportional hazards models.
    Results: Of 4106 SOTRs, the number (%) who were concordantly positive, concordantly negative, and discordant was 3787 (92.2%), 149 (3.6%), and 170 (4.2%), respectively. The adjusted hazard of PTLD was significantly higher among discordant SOTRs compared to concordantly positive SOTRs (aHR 2.6, 95% CI 1.04-6.6, p =.04) and lower compared to concordantly negative SOTRs (aHR 0.27, 95% CI 0.10-0.76, p <.001). The adjusted hazard of EBV+ PTLD among those with discordant serology was also significantly higher compared to the concordantly positive cohort (aHR 3.53, 95% CI 1.04-12.0, p =.04) and significantly lower compared to the concordantly negative cohort (aHR 0.23, 95% CI 0.06-0.82, p =.02).
    Conclusions: Risk of PTLD among SOTRs with discordant VCA and EBNA-1 may be intermediate between those with concordantly positive and negative serology. If confirmed in future studies, revision of national EBV serology reporting to include both VCA and EBNA results may be needed to optimize PTLD risk stratification.
    Mesh-Begriff(e) Adult ; Humans ; Epstein-Barr Virus Nuclear Antigens ; Herpesvirus 4, Human ; Epstein-Barr Virus Infections/complications ; Retrospective Studies ; Cohort Studies ; Capsid ; Lymphoproliferative Disorders/etiology ; Organ Transplantation/adverse effects ; Risk Assessment
    Chemische Substanzen EBV-encoded nuclear antigen 1 (O5GA75RST7) ; Epstein-Barr Virus Nuclear Antigens
    Sprache Englisch
    Erscheinungsdatum 2022-09-06
    Erscheinungsland Denmark
    Dokumenttyp Journal Article
    ZDB-ID 1476094-0
    ISSN 1399-3062 ; 1398-2273
    ISSN (online) 1399-3062
    ISSN 1398-2273
    DOI 10.1111/tid.13933
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  9. Artikel ; Online: Reply to Hage and Schuurmans.

    Kates, Olivia S / Rakita, Robert M / Lease, Erika D / Fisher, Cynthia E / Limaye, Ajit P

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

    2020  Band 73, Heft 9, Seite(n) e2833–e2834

    Sprache Englisch
    Erscheinungsdatum 2020-10-26
    Erscheinungsland United States
    Dokumenttyp Letter ; Comment
    ZDB-ID 1099781-7
    ISSN 1537-6591 ; 1058-4838
    ISSN (online) 1537-6591
    ISSN 1058-4838
    DOI 10.1093/cid/ciaa1633
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  10. Artikel ; Online: Emerging evidence to support not always "just saying no" to SARS-CoV-2 positive donors.

    Kates, Olivia S / Fisher, Cynthia E / Rakita, Robert M / Reyes, Jorge D / Limaye, Ajit P

    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

    2020  Band 20, Heft 11, Seite(n) 3261–3262

    Mesh-Begriff(e) COVID-19/epidemiology ; COVID-19/transmission ; DNA, Viral/analysis ; Disease Transmission, Infectious/prevention & control ; Humans ; Organ Transplantation/methods ; Pandemics ; SARS-CoV-2/genetics ; Tissue Donors ; Tissue and Organ Procurement/methods
    Chemische Substanzen DNA, Viral
    Schlagwörter covid19
    Sprache Englisch
    Erscheinungsdatum 2020-06-18
    Erscheinungsland United States
    Dokumenttyp Letter
    ZDB-ID 2060594-8
    ISSN 1600-6143 ; 1600-6135
    ISSN (online) 1600-6143
    ISSN 1600-6135
    DOI 10.1111/ajt.16119
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

Zum Seitenanfang